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Abstract. Robotic-assisted radical prostatectomy (RARP) 
shows measurable advantages, compared to conventional open 
surgery, even if some aspects are, still, under debate. The 
aim of this study was to compare the potency recovery rate 
of patients with clinically localised prostate cancer treated 
by bilateral nerve-sparing (BNS) RARP or retropubic radical 
prostatectomy (RRP), and secondarily, the urinary continence 
recovery evaluation and the oncological efficacy. All patients 
treated with BNS-RARP or BNS-RRP for clinically localised 
prostate cancer, performed by a single dedicated surgeon, 
between January 2004 and December 2008, were enrolled 
in this non-randomised prospective comparative study. The 
International Index of Erectile Function (IIEF) and erection 
hardness score (EHS), in the form of a questionnaire, were 
self-administered to each patient pre-operatively and after 
12 months. The presence of surgical margins was consid-
ered as oncological outcome measure. Eighty-two patients 
underwent BNS-RARP while 48 underwent BNS-RRP. For 
BNS-RARP and BNS-RRP the median operative time was 
221 and 103 min, respectively (P<0.001; df=128; t=721.43),and 
intra-operative blood loss was 280 and 565 ml, respectively 
(P<0.001; df=128; t=1742.44). At a mean follow-up period of 
12.4±2.3 months, 12 patients (25%) in the BNS-RRP group and 
22 (26.8%) in the BNS-RARP group were considered potent 
with or without drugs (P=0.81). Moreover, we did not find any 
statistically significant difference between the 2 groups in 
terms of IEFF and EHS scores after treatment (17.21 vs. 16.98; 
P=0.16 and 2.1 vs. 2.0; P=0.54). On the other hand, statistically 
significant differences between the 2 groups were found in 
terms of faster urinary continence recovery and the presence 
of positive surgical margins (P<0.001, P=0.009). Shorter cath-
eterization duration (7 vs. 3 days) and post-operative hospital 
stays (8 vs. 4 days; P<0.001) were found in the BNS-RARP 
group compared to the BNS-RRP group. In conclusion, our 
results demonstrate that BNS-RARP does not improve erectile 
function recovery compared to open radical prostatectomy; 
however, it significantly improves urinary continence and 
decreases the presence of positive surgical margins.
Introduction
Radical prostatectomy (RP) is the gold standard treatment for 
patients with clinically localised prostate cancer (cT1-cT2) and 
a life expectancy of >10 years (1). Patient selection and surgical 
technique are the major determinants of post-operative erectile 
function (2). The shift from open to laparoscopic surgery repre-
sented a completely new experience for surgeons, who were 
exposed to surgical anatomy through a different perspective 
and were required to learn new surgical procedures and to deal 
with new surgical tools (2). Robotic systems have been recently 
introduced in order to reduce difficulties in performing complex 
laparoscopic urological procedures, particularly for non-lapa-
roscopic surgeons (3). Recent studies have demonstrated that 
robotic-assisted radical prostatectomy (RARP) has measurable 
advantages, when compared to both conventional open surgery 
and to conventional laparoscopic prostatectomy (4), due to the 
fact that RARP offers the additional advantages of x10 magni-
fied binocular, 3-dimensional visualization, motion scaling 
with tremor filtration, improved ergonomics and miniature 
wrested, articulating surgical instruments with 7 degrees of 
freedom (3). A number of studies comparing RARP with other 
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surgical approaches have demonstrated the improved func-
tional results of RARP. Particularly, Ficarra et al (3) showed 
that RARP offers better results than RRP in terms of urinary 
continence and erectile function recovery, with similar positive 
surgical margin rates. Moreover, Menon et al (5) demonsrtated 
that in a large series of patients, approximately 70% had recov-
ered erectile potency after 12 months following nerve-sparing 
RARP. These results may be due to the fact that RARP prevents 
damage to the neurovascular bundle by more precise dissection 
and prevents inadvertent incision, traction, or incorporation of 
the neurovascular bundle into the suture or clip. On the other 
hand, Krambeck et al (6) reported no significant difference in 
potency rates at 1-year follow-up. Thus, the question of whether 
the robotic-assisted laparoscopic technique improves the 
chances of recovering erectile function remains under debate. 
The aim of this study was to compare the potency recovery 
rate of a contemporary series of patients with clinically local-
ised prostate cancer treated by bilateral nerve-sparing (BNS) 
RARP or retropubic radical prostatectomy (RRP), performed 
by a single surgeon. The secondary aim of this study was the 
evaluation of urinary continence recovery and the oncological 
efficacy evaluated as the presence of surgical margins.
Materials and methods
Study design. To compare the potency recovery rate between 
the 2 groups of patients, those who underwent BNS RARP or 
BNS-RRP, all consecutive patients who had undergone BNS RP 
at the same Urological Unit performed by a single dedicated 
surgeon, between January 2004 and December 2008 were 
selected for this prospective study. We compared 2 series 
of patients who had undergone BNS-RARP and BNS-RRP 
performed by a single dedicated surgeon, after a learning 
curve of at least 50 procedures. There is no evidence-based 
recommendation for how long a learning curve should be; 
howver, the majority of published reports on RARP suggest a 
minimum of 50 cases (7). Each patient was evaluated for the 
following parameters: age, co-morbidity (age-adjusted Charlson 
co-morbidity index), pre-operative total PSA, biopsy Gleason 
score, clinical stage according to the 2002 TNM system, peri-
neural and endovascular invasion, pathological extension of the 
primary tumor according to the 2002 Tumor Node Metastasis 
(TNM) system (8) and presence of positive surgical margins. 
Moreover, the International Index of Erectile Function (IIEF) 
and erection hardness score (EHS), in the form of a question-
naire, were self-administered to each patient, pre-operatively and 
after 12 months. Follow-up data were compared and analysed. 
Patients with no further information available at follow-up were 
excluded from the study. The local research ethics committee 
approved the study. Written informed consent was obtained 
from all patients. The study was conducted in line with Good 
Clinical Practice guidelines and with the ethical principles laid 
down in the latest version of the Declaration of Helsinki.
Eligibility for the study. Inclusion criteria were as follows: 
patients who had undergone BNS-RARP or BNS-RRP for 
clinically localised prostate cancer (clinical stage <cT2b), 
PSA <10 ng/ml, Gleason score <7, life expectancy >10 years, 
pre-operative IIEF score >25 in accordance with Cappelleri 
et al (9) and an EHS of 4 (10). Patients also had to be in a 
stable relationship (with the same partner for ≥6 months). 
Exclusion criteria were the presence of other neoplastic, lower 
urinary tract or major concomitant diseases. Patients who 
had undergone previous abdominal surgery were excluded. 
All patients with urinary incontinence or erectile dysfunction 
were also excluded. Moreover, we also excluded all patients 
receiving phosphodiesterase type 5 (PDE5) inhibitors and/or 
an intracorporal injection (5 µg/week) of alprostadil (PGE 1). 
We only enrolled patients who had undergone BNS RP by a 
single dedicated surgeon.
Surgical technique procedures and follow-up schedule. In 
brief, RRP was performed as described by Walsh (11) in 1998. 
RARP was performed as follows: all cases were approached 
transperitoneally, dissecting the anterolateral surface of the 
prostate using an intrafascial technique and developing the 
plane between the prostatic capsula and the thin surrounding 
periprostatic fascia. The lateral pedicles were controlled 
making every attempt to preserve the neurovascular bundles. 
Vesicourethral anastomosis was performed as described by 
Van Velthoven et al (12). In accordance with the European 
Association of Urology (EAU) guidelines, no patient had 
undergone lymphadenectomy due to of having lymphnode 
metastasis (1). It was suggested that all patients undergo an 
early penile rehabilitation with PDE5 inhibitors twice a week 
for 6 months after RP. All patients with positive margins at 
histopathological evaluation were included in the standard 
follow-up controls, but were excluded from the functional 
outcome analysis. Biochemical failure was defined as 2 or 
more consecutive ultrasensitive PSA values of >0.2 ng/ml (1). 
All biochemical failure patients underwent external beam 
radiotherapy and/or hormonal therapy, as suggested in the 
EAU guidelines (1).
Questionnaires and clinical evaluation. We used the IIEF 
questionnaire as it has a higher level of validity, accuracy and 
reliability, and is more stable than single-item assessment. 
In accordance with Briganti et al (13), recovery of erectile 
function following BNS-RP was defined as an IIEF domain 
score of ≥22. We used the EHS due to the fact that it is a 
simple, practical tool for clinical use (14). None of the patients 
received neoadjuvant or adjuvant hormonal therapy and none 
of the patients underwent adjuvant radiation therapy. Continent 
patients were defined by use of 0 or 1 safety pad/day. Outcome 
measures were erectile function recovery, urinary function 
recovery and the percentage of positive surgical margins. 
Moreover, the Clavien-Dindo classification of post-operative 
complications was used (15).
Pathological staging. All specimens, including prostate and 
seminal vesicles were examined microscopically after routine 
preparation. The prostate was weighed and cut as whole-mount 
4-mm sections. All specimens were scored according to the 
Gleason grading system. Microscopic extension of malignant 
cells to the inked surface of the resected specimen was inter-
preted as a positive surgical margin. The pathological stages 
were assigned according to the 2002 TNM classification (8).
Statistical analysis. As a null hypothesis we assumed that there 
were no differences between the 2 groups in terms of potency 
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recovery rate, urinary continence recovery and the presence 
of surgical margins. The comparison of continuous variables 
between the 2 groups was performed with the Student's t-test, 
Mann-Whitney U test or Wilcoxon test, where appropriate. 
Time-related changes of continuous variables were analysed 
using the paired t-test. Pearson's Chi-square and Fisher's exact 
test were used to compare categorical variables and propor-
tions, where appropriate. A two-tailed probability P-value 
of <0.05 was considered to indicate a statistically significant 
difference. All statistical calculations were performed with 
the Statistical Package for Social Sciences v.11.0 (SPSS, Inc., 
Chicago, IL, USA). Statistical tests were carried out with a 
two-sided α level of 0.05.
Results
Among 400 consecutive patients undergoing RP during the 
wide study period, 135 patients were eventually eligible for 
the present study. This trial ultimately included 130 patients. 
Eighty-two received BNS-RARP and 48 BNS-RRP. Patient 
characteristics, clinical and laboratory data at enrollment are 
described in Table I, according to the group. At the baseline, 
all patients were pre-operatively continent and potent. The 
2 groups are statistically comparable. For BNS-RARP and 
BNS-RRP the median operative time was 221 and 103 min, 
respectively (P<0.001; df=128; t=721.43) and intra-operative 
blood loss was 280 and 565 ml, respectively (P<0.001; df=128; 
t=1742.44). All perioperative data and complications are 
described in Table II.
Functional outcome evaluation. All patients correctly under-
went penile rehabilitation with oral PDE5 inhibitors twice in a 
week for 6 months after surgical treatment. No patient discon-
tinued the treatment. All data are summarised in Table III.
Erectile function. In patients undergoing BNS-RRP we docu-
mented the following post-operative results: return to baseline 
of the erectile function (IIEF score >25 and EHS score 4) was 
present in 3 patients (6%), with a mean IIEF score of 28.5 
(range 27-30) and pharmacological-induced potency (IIEF 
score >25 and EHS score 4) was present in 9 patients (19%), 
with a mean IIEF score of 26.3 (range 25-30), while we 
registered the absence of recovery of the erectile function in 
36 patients (75%). Then, 12 patients (25%) were considered 
potent, with a mean IIEF score of 27.2 (range 25-30). On 
the other hand, in patients undergoing BNS-RARP, the data 
showed the following post-operative results: return to base-
line of the erectile function (IIEF score >25 and EHS score 
was 4) was present in 3 patients (4%), with a mean IIEF score 
of 27.9 (range 27-30) and pharmacological-induced potency 
(IIEF score >25 and EHS score 4) in 19 patients (23%), with a 
mean IIEF score of 26.7 (range 25-30), while we registered the 
Table I. Clinical and pathological characteristics of all patients at the time of surgery.
 Radical prostatectomy
 -------------------------------------------------------------------------
Characteristics Total BNS-RRP BNS-RARP P-value
Patients enrolled 130 48 82 -
Mean age 68.1±8.7 66.7±9.9 68.1±2.3 0.22
  Educational level    0.004
  Primary school   55 25 30 
  High school   34 15 19 
  Degree   41   8 33 
Pre-operative tPSA   8.2±1.1   7.9±2.1   8.3±3.1 0.38
Biopsy Gleason score    0.15
  6 (3+3)   67 29 38 
  7 (3+4)   41 12 29 
  7 (4+3)   22   7 15 
Clinical stage    0.59
  cT1   56 31 25 
  cT2a   74 37 37 
Charlson CI   6.1±1.2   6.3±1.1   6.0±0.8 0.07
Pre-operative IIEF 28.3±1.1 28.9±0.9 29.1±1.3 0.34
Pre-operative EHS     4   4   4 -
BNS, bilateral nerve-sparing; RRP, retropubic radical prostatectomy; RARP, robotic-assisted radical prostatectomy; tPSA, total PSA; Charlson 
CI, Charlson co-morbidity index; IIEF, International Index of Erectile Function; EHS, erection hardness score.
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Table II. Perioperative data and complications.
 Radical prostatectomy
 -------------------------------------------------------------------------------------
 BNS-RRP BNS-RARP P-value
Median operative time 221 103 <0.001
Intra-operative blood loss 280 565 <0.001
Pathologic stage   -
  pT2a 11 22 
  pT2b 8 13 
  pT2c 12 19 
  pT3a 12 21 
  pT3b 5 9 
Gleason score   -
  6 (3+3) 23 38 
  7 (3+4) 18 27 
  7 (4+3) 7 17 
Margin status positive 14 8 0.009
Clavien-Dindo (patients)   -
  No complications 43 74 
  Grade I-II 4 7
  Grade III 1 1
Median catheterization time 7 3 <0.001
Median hospitalization time 8 4 <0.001
BNS, bilateral nerve-sparing; RRP, retropubic radical prostatectomy; RARP, robotic-assisted radical prostatectomy.
Table III. Functional outcome evaluation.
 Radical prostatectomy
 ------------------------------------------------------------------------------
 BNS-RRP BNS-RARP P-value
Erectile function
  Total IIEF mean 17.21 16.98 0.16
  Total EHS 2.12.0 0.54
  Absence of recovery, n (%) 36 (75) 60 (73.1) -
  Return to baseline (with drugs), n (%) 9 (18.7) 19 (23.2) -
    IIEF mean score 26.3 26.7 
    EHS median 4 4 
  Return to baseline (without drugs), n (%) 3 (6.3) 3 (3.7) -
    IIEF mean score 28.5 27.9 
    EHS median 4 4 
Urinary function
  Continent patients 47 (97.9) 78 (95.1) 0.74
  Continence recovery time (months) 6.9±1.4 4.1±0.73 <0.001
BNS, bilateral nerve-sparing; RRP, retropubic radical prostatectomy; RARP, robotic-assisted radical prostatectomy; IIEF, International Index 
of Erectile Function; EHS, erection hardness score.
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absence of recovery of erectile function in 60 patients (73%). 
Then, 22 patients (26.8%) were considered potent, with a mean 
IIEF score of 27.1 (range 25-30). We did not find statistically 
significant differences in erectile function recovery achieved 
after BNS-RARP, when compared with BSN-RRP. In fact, we 
did not find statistically significant differences between the 
2 wide groups in terms of IEFF and EHS scores after treat-
ment (17.21 vs. 16.98; P=0.16 and 2.1 vs. 2.0; P=0.54).
Urinary function. Twelve months after the procedures, 
47 patients who had undergone BNS RRP (98%) and 
78 patients who had undergone BNS-RARP (95%) were conti-
nent (P=0.74; Chi-square, 0.10; df=1). However, we found that 
patients who had undergone BNS-RARP had a much more 
rapid continence recovery than those who had undergone 
BNS-RRP (4.1±0.73 vs. 6.9±1.4 months, respectively (P<0.001; 
df=128; t=14.9).
Pathological and oncological outcome. At pathological eval-
uation, in the BNS-RRP group we documented the following 
findings: 31 pT2 (64.5%), 17 pT3 (35.5%); Gleason score: 
23 6 (47.9%), 18 7 (3+4) (37.5%) and 7 (4+3) (14.6%). On the 
other hand, in the BNS-RARP group: 52 pT2 (63.4%), 30 pT3 
(36.6%); Gleason score: 38 6 (46.3%), 27 7 (3+4) (32.9%) 
and 17 (4+3) (20.8%). Overall positive surgical margins were 
found in 14 patients who had undergone BNS-RRP (30%) 
and in 8 patients who had undergone BNS-RARP (10%) 
(P=0.009; df=1; Chi-square, 6.79); moreover, positive surgical 
margins in patients with localised prostate cancer were found 
in 3 patients who had undergone BNS-RRP and in 2 patients 
who had undergone BNS-RARP.
Complications and post-operative characteristics. We docu-
mented overall complication rate of 10.4% in the BNS-RRP 
group (5 patients) and of 9.7% in the BNR-RARP group 
(8 patients). Specifically, we registered 6 low grade complica-
tions (Clavien I and II) in 4 patients in the retropubic serie and 
9 low grade complications in 7 patients in the robotic serie. 
Data showed, moreover, 2 high grade complications in 1 patient 
in the retropubic and 1 in the robotic group. We did not show 
Clavien V complication (death) in both group. Patients of the 
BNS-RRP group removed the catheter in 7 post-operative day 
and were discharged in 8 post-operative day, while patients of 
the BNS-RARP group removed the catheter in 3 post-operative 
day and were discharged in 4 post-operative day, respectively 
(P<0.001; df=128; t=24.4).
Discussion
Currently, the main challenge in the treatment of prostate 
cancer patients is the improvement of quality of life, due to the 
fact that oncological outcomes have improved (6). The use of 
robotic-assisted laparoscopic radical prostatectomy has been 
purposed in order to obtain better results in terms of quality of 
life and oncological outcomes (16). However, the question of 
whether the robotic-assisted laparoscopic technique improves 
the chances of recovering from urinary continence and 
recovering erectile function remains under debate. The cost 
effectiveness of the new technique remains an issue. RARP 
is associated with a higher cost and a much longer learning 
curve than radical open prostatectomy and radical laparoscopic 
prostatectomy (3). In our series of patients, we did not find any 
statistically significant difference between the 2 groups in 
terms of erectile function recovery when compared to open RP. 
However, compared to open RP, RARP significantly improved 
continence recovery and decreased the presence of positive 
surgical margins. Our findings differ from those reported by 
other authors. Rocco et al (17) reported higher potency rates 
after RARP than open RP at 3, 6 and 12 months (RARP 31, 43 
and 61%, respectively; open RP 18, 31 and 41%, respectively; 
P=0.006, 0,045 and 0.003, respectively). Moreover, Tewari 
et al (18) compared 110 patients who had undergone RRP with 
200 patients who had undergone RARP. In this study, only 
patients who had BNS-RRP or BNS-RARP and were potent 
pre-operatively were included. Following RARP, the patients 
had a more rapid erectile function recovery, with 50% at a 
mean follow-up of 180 vs. 440 days after RRP (P<0.05) (18). 
Clearly, it is well known that RARP has greater incidence 
of neurovascular bundle preservation and faster convalescence 
than RRP, but it is also well known, that the success of the 
nerve-sparing technique is determined by the accurate selec-
tion of patients (19-20). As suggested by Novara et al (21), 
in the era of robotic surgery, the key point for the success 
of the nerve-sparing technique is the accurate selection of 
patients. At the age of <65 years, the absence of associated 
co-morbidities and good pre-operative erectile function are the 
most important pre-operative factors to select those patients 
for whom BNS-RARP can achieve the best results (21). Even 
though we enrolled patients with a pre-operative IIEF score 
of >25, an EHS of 4 and who were in a stable relationship for 
≥6 months, we registered the absence of recovery of erectile 
function in 36 patients (75%) in the BNS-RRP group and in 
60 patients (73%) in the BNS-RARP group. The reason for this 
low erectile recovery rate may be that in our series of patients, 
the main parameter affecting erectile function recovery was 
an age of >65 years. Ninety-eight patients (75.3%), were 
>65 years old and this is possibly the reason for our results. 
However, in everyday clinical practice, most patients are 
>65 years old. The small number of enrolled patients, however, 
did not allow us to perform a multivariate analysis in order to 
establish the independent factors affecting erectile recovery. In 
this sense, the relatively small number of patients was the first 
main limitation of our study. On the other hand, we observed 
a good continence recovery rate in both groups of patients, 
demonstrating that age is not a factor affecting continence 
recovery probability. Another limitation of this study was the 
short-term follow-up period. However, several studies have 
stated that urinary and sexual function recovery can be evalu-
ated within 12 months and that the probability of recovery 
after this time is very low (6). However, the stronger point of 
this study was the fact that all patients had undergone RP by 
a single dedicated surgeon after a learning curve of at least 
50 patients. Finally, we found a higher frequency of positive 
surgical margins in the BNS-RRP group compared with the 
BNS-RARP group. These data, however, are in line with the 
literature (3).
In conclusion, we noted that, in our series of patients, 
BNS-RARP did not improve erectile recovery when compared 
to open RP, but allowed for a more rapid recovery from 
urinary continence and improved the oncological outcome in 
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terms of lower positive surgical margins prevalence. However, 
prospective studies with longer follow-up periods and a greater 
number of patients are required to compare the oncological 
and functional results.
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